Terms: = Ovarian cancer AND FLI1, SIC-1, 2313, ENSG00000151702, Q01543, EWSR2 AND Treatment
4 results:
1. Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.
Ye H; Lin M; Li R; Qin S; Hou G; Chen H; Li X
J Ovarian Res; 2021 Jan; 14(1):21. PubMed ID: 33509230
[TBL] [Abstract] [Full Text] [Related]
2. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
Chung V; Mansfield AS; Braiteh F; Richards D; Durivage H; Ungerleider RS; Johnson F; Kovach JS
Clin Cancer Res; 2017 Jul; 23(13):3277-3284. PubMed ID: 28039265
[No Abstract] [Full Text] [Related]
3. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma.
Kelleher FC; Cain JE; Healy JM; Watkins DN; Thomas DM
Pharmacol Ther; 2012 Nov; 136(2):153-68. PubMed ID: 22906929
[TBL] [Abstract] [Full Text] [Related]
4. Adenovirus 5 early region 1A does not induce expression of the ewing sarcoma fusion product EWS-fli1 in breast and ovarian cancer cell lines.
Meric F; Liao Y; Lee WP; Pollock RE; Hung MC
Clin Cancer Res; 2000 Oct; 6(10):3832-6. PubMed ID: 11051226
[TBL] [Abstract] [Full Text] [Related]
